HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING

Late-breaking Phase 2 proof-of-concept study in Prader-Willi syndrome accepted for poster presentation
PLYMOUTH MEETING, Pa., May 10, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. , a... | May 10, 2023

Related Keywords

United States ,Kumar Budur ,Luis Sanay ,Drug Administration ,Exchange Commission ,Paragon Biosciences ,Prnewswire Harmony Biosciences Holdings Inc ,Late Breaking Phase ,Biosciences Holdings ,Annual Meeting ,Associated Professional Sleep Societies ,Chief Medical Officer ,Meaningful Improvements ,Pooled Analysis ,Randomized Clinical Trials ,Presentation Date ,Board Number ,Breast Milk ,Healthy Lactating Women ,Pregnancy Registry ,Pitolisant Exposure ,Pregnant Women ,Their Offspring ,Safety Results ,Placebo Controlled Proof ,Signal Detection Study ,Prader Willi Syndrome ,Full Prescribing Information ,Harmony Biosciences ,Plymouth Meeting ,Private Securities Litigation Reform Act ,Annual Report ,Biosciences Media Contact ,Biosciences Investor Contact ,Harmony Biosciences Holdings ,Nc Stock Exchange ,News ,Information ,Press Release ,Hase , ,Study ,N ,Yndrome ,Accepted ,Or ,Poster ,Bay ,023 ,Armony ,Iosciences Hrmy Us4131971040 ,